These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15694515)

  • 1. The effects and costs of expanding the coverage of immunisation services in developing countries: a systematic literature review.
    Pegurri E; Fox-Rushby JA; Damian W
    Vaccine; 2005 Feb; 23(13):1624-35. PubMed ID: 15694515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries.
    Munk C; Portnoy A; Suharlim C; Clarke-Deelder E; Brenzel L; Resch SC; Menzies NA
    BMC Health Serv Res; 2019 Oct; 19(1):741. PubMed ID: 31640687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we use contingent valuation to assess the demand for childhood immunisation in developing countries?: a systematic review of the literature.
    Yeung RY; Smith RD
    Appl Health Econ Health Policy; 2005; 4(3):165-73. PubMed ID: 16309334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries.
    Portnoy A; Resch SC; Suharlim C; Brenzel L; Menzies NA
    Value Health; 2021 Jan; 24(1):67-69. PubMed ID: 33431155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
    Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
    Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of cost-effectiveness analysis for pediatric immunization in developing countries.
    Gauvreau CL; Ungar WJ; Köhler JC; Zlotkin S
    Milbank Q; 2012 Dec; 90(4):762-90. PubMed ID: 23216430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costs, effects and cost-effectiveness of strategies to increase coverage of routine immunizations in low- and middle-income countries: systematic review of the grey literature.
    Batt K; Fox-Rushby JA; Castillo-Riquelme M
    Bull World Health Organ; 2004 Sep; 82(9):689-96. PubMed ID: 15628207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of the incremental costs of interventions that increase immunization coverage.
    Ozawa S; Yemeke TT; Thompson KM
    Vaccine; 2018 Jun; 36(25):3641-3649. PubMed ID: 29754699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs of scaling up vaccination in the world's poorest countries.
    Bishai D; McQuestion M; Chaudhry R; Wigton A
    Health Aff (Millwood); 2006; 25(2):348-56. PubMed ID: 16522576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking progress towards universal childhood immunisation and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunisation coverage.
    Lim SS; Stein DB; Charrow A; Murray CJ
    Lancet; 2008 Dec; 372(9655):2031-46. PubMed ID: 19070738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Get Cost-Effectiveness Analysis Right? The Case of Vaccine Economics in Latin America.
    Glassman A; Cañón O; Silverman R
    Value Health; 2016 Dec; 19(8):913-920. PubMed ID: 27987640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
    Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
    Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.
    Ryser MD; McGoff K; Herzog DP; Sivakoff DJ; Myers ER
    Epidemics; 2015 Jun; 11():32-47. PubMed ID: 25979280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment.
    Lu C; Michaud CM; Gakidou E; Khan K; Murray CJ
    Lancet; 2006 Sep; 368(9541):1088-95. PubMed ID: 16997663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analyses of rubella and rubella vaccines: a global review.
    Hinman AR; Irons B; Lewis M; Kandola K
    Bull World Health Organ; 2002; 80(4):264-70. PubMed ID: 12075361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Urgent global response" needed to vaccinate the world's children.
    Baleta A
    Lancet; 2002 Apr; 359(9315):1414. PubMed ID: 11978352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.